Trasylol (generic: aprotinin) is a blood clotting drug administered to patients undergoing heart surgery to prevent bleeding. Recently, Trasylol has been linked to renal (kidney) failure and even death. Our St. Louis, MO Defective Drug Lawyers have investigated this dangerous drug and are currently accepting cases against its manufacturer, Bayer Pharmaceuticals. Currently, Trasylol is the target of class action lawsuits in other states.
History of Trasylol
The drug was approved by the Food and Drug Administration (FDA) in 1993, and has since been found to have significant health risks. Studies have shown Trasylol to contribute to post surgery renal (kidney) failure and a 64% increased chance of death.
Why Bayer Should be Held Accountable for Trasylol Injuries
Bayer was aware of the health risks associated with this drug as early as the 1980’s, when it was first tested in labs. Trasylol was initially approved by the FDA for heart surgery patients with a high risk of bleeding. Even with this limited use, however, patients were found to run a significantly increased risk of renal failure resulting in the need for dialysis. Dr. Nicholas Kouchoukos of Missouri Baptist Medical Center, one of the nation’s leading heart surgeons, supports that patients most commonly experienced renal failure, lifelong decreased kidney function, as well as the increased risk for heart attack and stroke.
Bayer’s repeated failure to warn the public of the dangers of Trasylol make them liable for the effects of this defective drug. If you or someone you love has undergone heart surgery and since suffered renal failure, stroke, heart attack or even death, Trasylol may be to blame. It is crucial that you speak with a Missouri drug recall attorney who experienced in defective drug litigation immediately. Cases involving Trasylol are time sensitive and often patients are not aware that they have received the drug until they experience its devastating effects.
Independent research of 10,000 patients undergoing heart surgery was conducted by Duke University Medical Center from 1996 to 2005. Researchers found patients who received Trasylol to be 6.5% more likely to die within 30 days of surgery than patients receiving alternative blood clotting drugs. Another study conducted from 2003 to 2006 of 78,000 patients found the risk of death in Trasylol patients to be 64% higher than that in patients who received an alternative drug. In 2006 the “New England Journal of Medicine” published yet another study showing Trasylol to be responsible for in excess of 10,000 to 11,000 cases of renal failure each year.
Studies such as this which show the risks of Trasylol did not prevent the FDA from expanding the approved use of the drug to include all heart surgery patients in 1998. This approval came with pressure from Bayer who was enjoying a profit of more the 3 million dollars a year from Trasylol and a project increase in profit to 7.5 million dollars a year.
In addition to the significant health risks associated with Trasylol, it is also more expensive than alternative clotting drugs available to heart surgery patients. Trasylol costs an average 1,400 dollars per dose. The drug’s cost combined with cost of resulting health complications totals nearly 1 billion dollars per year in the United States alone. It is often regrettable for victims of this defective drug to find out later that there are two alternative clotting drugs available to heart surgery patients. Tranexamic acid and aminocaproic acid both cost only 50 to 100 dollars per dose, and they have very few side effects.
In 2006 the “New England Journal of Medicine” published yet another study showing Trasylol to be responsible for in excess of 10,000 to 11,000 cases of renal failure each year. With so many studies showing the devastating effects of Trasylol, its manufacturer Bayer decided to conduct its own study. They hired Harvard professor Dr. Alexander Walker to analyze the records of 70,000 patients having taken Trasylol. Dr. Walker, like researchers before him, found Trasylol patients to have an increased risk of death and renal failure. The FDA held a meeting in 2006 to access the concerns surrounding Trasylol. With the profits Bayer had been enjoying from this drug, they made sure their findings were never made known to the FDA.
In November 2007 the FDA did finally request Trasylol be removed from the market. This request came largely in response to a Canadian based study of the Trasylol which had to be canceled because patients were dying rapidly.
From the time of the FDA’s meeting in 2006 until their decision to withdraw the drug in late 2007, it is estimated that 1,000 patients per month died from complication due to Trasylol. Missouri law protects those suffering from debilitating renal failure, complications from stroke, or families suffering the loss of a loved one, due to Trasylol. If you or someone you love has been adversely affected by Trasylol it is important to contact a Missouri personal injury lawyer immediately. These cases are time sensitive and if you do not move quickly to secure evidence, it can be lost forever.
How Our Lawyers Can Help
The drug liability lawyers at E. Ryan Bradley have over thirty years of experience handling lawsuits. We have investigated Trasylol and have determined the actions of Bayer warrant valid legal claims for injuries caused by this defective drug. Contact E. Ryan Bradley today and speak with an experienced drug liability lawyer about your case for free.